Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2008-03-04

Clinical Trial Update: Humanized LL2IGG to Treat Systemic Lupus Erythematosus [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating a humanized LL2IgG for systemic lupus erythematosus has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • LL2IgG

Snippet

Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Conditions: Systemic Lupus Erythematosus | Phase 1 | Status: COMPLETED